Short answer
Cytek Biosciences, Inc. (CTKB) filed an 8-K current report with the SEC on August 24, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Jury verdict in Beckman Coulter patent infringement action, decided in the U.S. District Court for Delaware.
Cytek Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Jury verdict in Beckman Coulter patent infringement action, decided in the U.S. District Court for Delaware
- Litigation outcome creates potential intellectual property, product availability and financial exposure for Cytek
- Company announcement dated August 21, 2026, with details in Exhibit 99.1
Item 8.01 · Other Events
- Jury verdict favored Cytek on three of four asserted Beckman Coulter patent claims
- $20 million lost-profit award and $36.11 million royalty award for one claim
- Cytek plans post-verdict motions challenging doctrine-of-equivalents infringement and damages
- Potential appeal and ongoing royalty obligations create additional financial and operating uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cytek Biosciences, Inc. 8-K filings
Get the next CTKB 8-K as it lands
Follow CTKB for push alerts, or ask the research agent what this filing means.